Subscribe Us

header ads

Recents

header ads

Assisted Reproductive Technology Market Size At Around US$ 53.1 Bn In 2030

 The assisted reproductive technology market would grow at a CAGR of 8.12% over the predicted time frame. The market is expected to increase in value from US$ 28.44 Bn in 2022 to US$ 53.1 Bn in 2030.

Assisted Reproductive Technology Market Size 2022 To 2030

Key Takeaways:

  • Europe region has dominated the market in 2021 with a 37.8% of the revenue share.
  • By product, the accessory & disposable segment accounted for 51% revenue share in 2021.
  • By end-uses, the fertility clinics & other facilities segment has captured 79.9% of the overall revenue share in 2021. 
  • By type, the IVF segment has accounted for the highest revenue share of around 93.5% in 2021.

The on assisted reproductive technology Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2329

A recent report provides crucial insights along with application based and forecast information in the Global Assisted reproductive technology Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Assisted reproductive technology market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Assisted reproductive technology market are included as given below:

Assisted reproductive technology Market Key Players

  • Vitrolife AB
  • Thermo Fisher Scientific, Inc
  • The Cooper Companies, Inc (Cooper Surgical Inc.)
  • Progyny Inc.
  • Oxford Gene Technology
  • Millendo Therapeutics, Inc
  • Merck KGaA (EMD Serono, Inc)
  • Genera Biomedx
  • Fujifilm Holdings Corporation (Irvine Scientific Sales Company)
  • Cook Medical Inc
  • Ferring B.V.
  • Bloom IVF Centre
  • European Sperm Bank
  • Microm U.K. Ltd
  • Cosmos Biomedical Ltd
  • Cryolab Ltd

Market Segments

By Product

  • Instrument
    • Laser systems
    • Micromanipulator
    • Cabinet
    • Ovum aspiration pump
    • Imaging systems
    • Incubator
    • Cryosystem
    • Sperm separation system
    • Others
  • Accessory & Disposable 
  • Reagents & media
    • Embryo culture media
    • Ovum processing media
    • Semen processing media
    • Cryopreservation media

By Technology

  • In-Vitro Fertilization (IVF)
    • Fresh Donor
    • Frozen Donor
    • Fresh Non-Donor
    • Frozen Non-Donor
  • Artificial Insemination
    • Intrauterine Insemination
    • Intracervical Insemination
    • Intravaginal Insemination
    • Intratubal Insemination

By Diagnosis

  • Ovulation Testing
  • Hysterosalpingography

By End-User 

  • Ambulatory surgical centers
  • Hospitals
  • Clinics
  • Diagnostic centers
  • Gynecology Centers
  • Feminist Health Centers
  • IVF Centers

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Report Objectives

  • To define, describe, and forecast the global assisted reproductive technology market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the assisted reproductive technology market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Assisted Reproductive Technology Market 

5.1. COVID-19 Landscape: Assisted Reproductive Technology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Assisted Reproductive Technology Market, By Product

8.1. Assisted Reproductive Technology Market, by Product, 2022-2030

8.1.1. Instrument

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Accessory & Disposable

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Reagents & media

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Assisted Reproductive Technology Market, By Technology

9.1. Assisted Reproductive Technology Market, by Technology, 2022-2030

9.1.1. In-Vitro Fertilization (IVF)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Artificial Insemination

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Assisted Reproductive Technology Market, By Diagnosis 

10.1. Assisted Reproductive Technology Market, by Diagnosis, 2022-2030

10.1.1. Ovulation Testing

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Hysterosalpingography

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Assisted Reproductive Technology Market, By End-User 

11.1. Assisted Reproductive Technology Market, by End-User, 2022-2030

11.1.1. Ambulatory surgical centers

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Hospitals

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Clinics

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Diagnostic centers

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Gynecology Centers

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Feminist Health Centers

11.1.6.1. Market Revenue and Forecast (2017-2030)

11.1.7. IVF Centers

11.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Assisted Reproductive Technology Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.1.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.1.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.2.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.2.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.2.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.2.7.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.2.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.3.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.3.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.3.7.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.4.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.4.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.4.7.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.5.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)

Chapter 13. Company Profiles

13.1. Vitrolife AB

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. The Cooper Companies, Inc (Cooper Surgical Inc.)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Progyny Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Oxford Gene Technology

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Millendo Therapeutics, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Merck KGaA (EMD Serono, Inc)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Genera Biomedx

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Fujifilm Holdings Corporation (Irvine Scientific Sales Company)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Cook Medical Inc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments